Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data
Source: SeekingAlpha
2026-01-16 12:28:55 ET
The share price of Malvern, Pennsylvania based Ocugen, Inc. ( OCGN ), a biotech specialising in developing gene therapies to treat eye diseases, fell by nearly 15% in trading yesterday, after the company shared data from a Phase 2 clinical study evaluating its therapy OCU410 (AAV5-RORA) in the indication of geographic atrophy ("GA") secondary to dry age-related macular degeneration ("dAMD"). ...
Read the full article on Seeking Alpha
For further details see:
Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data
Ocugen, Inc.
NASDAQ: OCGN
OCGN Trading
5.51% G/L:
$2.4268 Last:
11,494,452 Volume:
$2.46 Open:
OCGN Latest News
March 04, 2026 08:15:00 am
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
OCGN Stock Data
$478,717,026
313,395,708
0.26%
38
N/A
Biotechnology & Life Sciences
Healthcare
US
Malvern
